title: [Metastatic Crohn's disease. Response to adalimumab dose intensification].
abstract: Inflammatory bowel disease is accompanied by extraintestinal manifestations in a high percentage of patients. Cutaneous lesions are the second most prevalent of these manifestations, and within these, metastatic Crohn's disease is one of the least common, being the least frequent specific cutaneous manifestation of Crohn's disease. This entity includes cutaneous and subcutaneous lesions with a non-caseating granulomatous appearance on histological analysis identical to that of Crohn's disease. These lesions are not found adjacent to the digestive tract. Due to the low prevalence of these manifestations, conclusive trials on the treatment of choice have not been performed and there is no well-defined therapeutic strategy. Distinct therapies with varying results have been reported. We report the case of a female patient with longstanding and complex Crohn's disease who developed metastatic cutaneous manifestations while receiving adalimumab. The cutaneous manifestations responded well to dose intensification of this drug. A review of the literature is provided.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Torrecárdenas, Almería, Spain. alatriste83@hotmail.com
authors.forename: Marta
authors.initials: M
authors.lastname: Lázaro Saéz
authors.forename: Alvaro
authors.initials: A
authors.lastname: Hernández Martínez
authors.forename: Roger Álvaro
authors.initials: RÁ
authors.lastname: Bendezú García
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Rodríguez Manrique
authors.forename: Francisca
authors.initials: F
authors.lastname: Simón López
authors.forename: Emilia
authors.initials: E
authors.lastname: Medina Estévez
authors.forename: José Luis
authors.initials: JL
authors.lastname: Vega Sáenz
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D003424:Crohn Disease / Q000150:complications*; D005260:Female; D006801:Humans; D012074:Remission Induction; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab